Edited by griffiths susan a (1 risultati)

Autore: 
Perfeziona con la Ricerca avanzata

Perfeziona la tua ricerca

  • Libri (1)

a

Fascia di prezzo personalizzata (EUR)

a

  • Lingua: Inglese

    Editore: Kluwer Academic Publishers, 1998

    0792387325 / 9780792387329

    • Rilegato

    Da: Fireside Bookshop, Stroud, GLOS, Regno UnitoFireside Bookshop

    Venditore con 5 stelle
    Contatta il venditore

    Membro dell’associazione: PBFA

    Condizione: Usato - Come nuovo

    EUR 36,36

    EUR 29,42 spedizione 
    Spedito da Regno Unito a U.S.A.

    Quantità: 1 disponibile

    Cloth/Laminated Boards. Condizione: Like New. Condizione sovraccoperta: No d/j as Published. Type: Book Considerable investment has been made by both pharmaceutical and biotechnology companies in pharmaceutical products of biotechnology. However, because relatively few of these products have been marketed, lack of relevant experience means that uncertainty still surrounds the most appropriate strategy for their safety evaluation. The 13th CMR International Workshop, held in February 1997, provided the opportunity for regulatory authority and industry experts from Europe, Japan and the USA to share their experiences of designing safety evaluation programmes for specific product classes: colony stimulating factors, growth factors, hormones, interferons, interleukins, monoclonal antibodies for therapeutic use, and gene therapy products. Participants worked together to recommend those studies that should be considered for such safety evaluation, and those that may be unnecessary. These recommendations subsequently made a valuable contribution to the ICH guideline "Safety Studies for Biotechnological Products", which was finalized at ICH 4 in Brussels in July 1997.200pp.…